ARS Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $728.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $215.00K, a 36.39% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $264.00K, a 7.37% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was $249.00K, a 11.07% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-12-31 was $243.00K, a 11.96% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.15M, a 6.80% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $1.07M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $479.00K derived: sum of 2 quarters · filed 2022-11-02 | $728.00K 10-Q · filed 2022-11-02 | $971.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $513.00K 10-Q · filed 2022-08-11 | $756.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.09M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $249.00K 10-Q · filed 2022-05-12 | $492.00K derived: sum of 2 quarters · filed 2022-05-12 | $830.00K derived: sum of 3 quarters · filed 2022-11-02 | $1.11M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $581.00K derived: sum of 2 quarters · filed 2022-11-02 | $866.00K derived: sum of 3 quarters · filed 2022-11-02 | $1.15M 10-K · filed 2022-03-31 |
| 2021-09-30 | $338.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $623.00K derived: sum of 2 quarters · filed 2022-11-02 | $903.00K 10-Q · filed 2022-11-02 | $1.18M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $285.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $565.00K 10-Q · filed 2022-08-11 | $841.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.11M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $280.00K 10-Q · filed 2022-05-12 | $556.00K derived: sum of 2 quarters · filed 2022-05-12 | $826.00K derived: sum of 3 quarters · filed 2022-05-12 | $1.09M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $546.00K derived: sum of 2 quarters · filed 2022-03-31 | $811.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.07M 10-K · filed 2022-03-31 |
| 2020-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $535.00K derived: sum of 2 quarters · filed 2021-11-10 | $797.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $527.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $262.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |